A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

Recruiting

Phase 2

Phase 3

Daretabart with ChemotherapyA Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

Sponsor:

Renaissance Pharma Ltd.

Code:

NCT07549321

Conditions

High-Risk Neuroblastoma

Eligibility Criteria

Sex: All

Age: 1 - 18

Healthy Volunteers: Not accepted

Interventions

hu1418K322A + Temozolomide + Irinotecan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-29. This information was provided to ClinicalTrials.gov by Renaissance Pharma Ltd. on 2026-04-24.